These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1874602)

  • 1. Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. A Southwest Oncology Group study.
    Green JB; Green S; O'Toole RV; Alberts DS; Nahhas WA; Wallace DL
    Invest New Drugs; 1991 May; 9(2):191-3. PubMed ID: 1874602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.
    Alberts DS; Mason-Liddil N; Stock-Novack D; O'Toole RV; Abbott TM; Salmon SE
    Am J Clin Oncol; 1992 Apr; 15(2):146-9. PubMed ID: 1553903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study.
    Miller TP; Dahlberg S; Salmon SE; Williamson SK; Belt RJ; Dana BW; Fisher RI
    J Clin Oncol; 1991 Jul; 9(7):1204-9. PubMed ID: 2045860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
    Ringenberg QS; Propert KJ; Muss HB; Weiss RB; Schilsky RL; Modeas C; Perry MC; Norton L; Green M
    Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
    Vaughn CB; Salmon SE; Fleming TR
    Invest New Drugs; 1990 Feb; 8(1):81-5. PubMed ID: 2188929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
    McGuire WP; Blessing JA; Berman ML
    Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    McGuire WP; Blessing JA; Yordan E; Beecham J
    Invest New Drugs; 1989 Jul; 7(2-3):235-8. PubMed ID: 2793379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esorubicin (4'-deoxydoxorubicin, NSC 267469) in advanced breast cancer. A phase II study of the CALGB.
    Muss HB; Van Echo D; Korzun AH; Henderson IC; Campbell T; Vogelzang NJ; Rice MA; Wood W
    Am J Clin Oncol; 1990 Jun; 13(3):233-7. PubMed ID: 2346128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of esorubicin (4'-deoxydoxorubicin) in locally advanced or metastatic head and neck carcinoma.
    Frustaci S; Gasparini G; Veronesi A; Tirelli U; Pacciarini MA; Crivellari D; Zagonel V; Monfardini S
    Invest New Drugs; 1987; 5(3):307-9. PubMed ID: 3667167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II evaluation of liposomal doxorubicin (Doxil) in recurrent or advanced leiomyosarcoma of the uterus: a Gynecologic Oncology Group study.
    Sutton G; Blessing J; Hanjani P; Kramer P;
    Gynecol Oncol; 2005 Mar; 96(3):749-52. PubMed ID: 15721421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of esorubicin in patients with advanced colorectal carcinoma.
    Fiore J; Kemeny N; Raymond V; Young C
    Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453
    [No Abstract]   [Full Text] [Related]  

  • 12. New anthracycline analogs in advanced breast cancer.
    Bonfante V; Ferrari L; Brambilla C; Rossi A; Villani F; Crippa F; Valagussa P; Bonadonna G
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1379-85. PubMed ID: 3470179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
    Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
    Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Thigpen JT; Blessing JA; Homesley H; Creasman WT; Sutton G
    Gynecol Oncol; 1989 Apr; 33(1):68-70. PubMed ID: 2703169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
    Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
    J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
    Rigas JR; Kris MG; Gralla RJ; Heelan RT; Marks LD
    Invest New Drugs; 1991 May; 9(2):187-90. PubMed ID: 1651908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of esorubicin in patients with advanced colorectal carcinoma and no prior chemotherapy: an Illinois Cancer Council Trial.
    Locker GY; Hoeltgen T; Kilton L; Krauss S; McNamara M; Blough R; Johnson C
    Cancer Treat Rep; 1987; 71(7-8):765-6. PubMed ID: 3300969
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma.
    Sridhar KS; Hussein AM; Benedetto P; Ardalan B; Savaraj N; Richman SP
    Cancer; 1992 Sep; 70(6):1591-7. PubMed ID: 1516010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma.
    Braich TA; Salmon SE; Robertone A; Alberts DS; Jones SE; Miller TP; Garewal HS
    Invest New Drugs; 1986; 4(3):269-74. PubMed ID: 3818231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685).
    Hochster H; Hunt M; Green M; Parkinson D; Smith T
    Invest New Drugs; 1990 Aug; 8(3):329-32. PubMed ID: 2272773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.